Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

China, Germany, Italy and Japan. The company does not do direct to consumer advertising outside the U.S. While OMD leads the account, Boehringer Ingelheim will also utilize other Omnicom ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...

The global veterinary dermatology market, valued at US$18.59 billion in 2024, is forecasted to grow at a robust CAGR of 8.5%, ...

The global canine arthritis treatment market stands at a valuation of USD 2.50 billion in 2024. Global demand for canine arthritis treatment medications is predicted to rise at a CAGR of 4.20% and ...

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by ...

The newly formed advisory board, which held its inaugural meeting last month, will identify opportunities to enhance scientific capabilities to ensure that OXB remains at the forefront of developing ...

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...

GBAC “Quantum Healthcare 2025” board blueprint—$3.2 B QC drug-discovery market, 42 % CAGR, 50–70 % faster R&D cycles ...

As pet insurance coverage increases and consumers demand higher standards of care, the veterinary dermatology drugs market is set to grow steadily. INDORE, INDIA, May 21, 2025 /EINPresswire.com/ -- ...